Background: Statins, beta-blockers, and angiotensin-converting enzyme
inhibitors/angiotensin II receptor blockers have been advocated by guidelines as secondary …

Purpose Secondary medication prevention after acute myocardial infarction (MI) is strongly
recommended in international guidelines, but actual use, adherence, and outcomes in …

Background Secondary prevention after acute myocardial infarction (AMI) requires long‐
term guideline‐directed medical therapy. However, the level of medication adherence …

Background Persistent use of secondary prevention therapies after acute myocardial
infarction (MI) is critical to optimizing long-term outcomes. Methods Medication persistence …

Background Secondary preventive drug therapy following acute myocardial infarction (AMI)
is recommended to reduce the risk of new cardiovascular events. The aim of this nationwide …

Purpose Clinical trials have shown that evidence-based secondary prevention medications
reduce mortality after acute myocardial infarction (AMI). Yet, these medications are generally …

Background Prior studies reported high guideline adherence for secondary prevention
medications (SPM) at hospital discharge in patients with acute myocardial infarction (AMI) …

Background Cardioprotective medication adherence can mitigate the risk of recurrent
cardiovascular events and mortality after acute myocardial infarction (AMI). We examined …

Background Guideline-recommended pharmacotherapy after myocardial infarction (MI) has
been shown to reduce cardiovascular morbidity and mortality. Our objectives were to …

Background Prior studies have demonstrated that patients with high-risk acute myocardial
infarction (AMI) are less likely to receive guideline-directed medications during …